High-growth economics has helped China emerge as the world's largest economy. Can these five risers follow in its footsteps?
Mylan posts Street-beating top and bottom lines behind strong growth in Q3 -- and successfully completing its agreement to purchase a portion of Abbott Labs' generics business could lead to more success ahead.
As all eyes look forward to the Biomet deal completion, Zimmer quietly inks strong growth from its reconstructive division and from international sales
Residents of these five chart-toppers out-earn their peers nationwide, but will these states' economies keep up?
These five nations have overcome the recession and prospered. But what makes them wealthy while other countries struggle?
Health insurance stocks have provided big rewards in 2014, but WellPoint, Centene, and UnitedHealth are building long-term windfalls for investors
AbbVie, Novo Nordisk, and Johnson & Johnson are three top healthcare stocks poised to delight investors for years to come
Though the Sapien valve has powered Edwards's shares to huge gains in 2014, competition is lurking to knock off this market leader.
Zimmer Holdings has underperformed its top orthopedic device competitors year to date, but this medical device leader could be poised for a big rebound in the years to come
Mylan has underperformed against other leading generic drug stocks in 2014, but that could change in the near future
Pandora also dives on earnings worries in a downbeat end to the week for investors.
Following a confirmation of its PDUFA date, AcelRx reeled in gains as regulatory approval looks likely
Strong top-line Q2 results and a full-year earnings boost help Universal's stock rally
Earnings season pushes UA and Nokia higher on a slow day for the market.
Pfizer's loss of Lipitor's patent in 2012 slammed this top pharma stock. Will losses of Lyrica and other top drugs in coming years offer a repeat performance?
After yesterday's ridiculous run-up, Puma investors took profits and pulled back from this blooming biotech
Shares of this medical device maker shot up by more than 10% early after a big FDA approval
Earnings season wallops this industrial leader, while General Motors also is hammered by its quarterly results.
A partnership with Johnson & Johnson exploring the company's bio-printed tissue in drug discovery leads to a big pop in shares
Earnings season pushed on and helped Hawaiian to a big gain, while Talisman roared higher on acquisitions speculation